Chronic Migraine
Conditions
Brief summary
Change from Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period
Detailed description
Change from Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period, Change from Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period., Percentage of Participants who Achieve at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days., Change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) Total Score at Week 12., Change from Baseline on the Pediatric Migraine Disability Assessment (PedMIDAS) Total Score at Week 12., Change from baseline in mean monthly headache days of at least moderate severity across the 12-week treatment period.
Interventions
DRUGAtogepant
Sponsors
AbbVie Deutschland GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period, Change from Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period., Percentage of Participants who Achieve at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days., Change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) Total Score at Week 12., Change from Baseline on the Pediatric Migraine Disability Assessment (PedMIDAS) Total Score at Week 12., Change from baseline in mean monthly headache days of at least moderate severity across the 12-week treatment period. | — |
Countries
Denmark, Hungary, Italy, Netherlands, Poland
Outcome results
None listed